Millie
your market intelligence analyst
Search Results
654 results
Your search is now limited to «Lung Cancer» expert search.
Business Wire 08/05/2020 08:00
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 CROWN study of LORBRENA® (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) met its primary endpoint by demonstrating significantly improved progression-free survival (PFS), as compared to XALKORI® (crizotinib).
More from Business Wire:
ClinicalTrials.gov 08/05/2020 07:27
Condition : Carcinoma, Non-Small Cell Lung Intervention : Drug: Durvalumab Sponsors : Georgetown University; AstraZeneca Not yet recruiting.
More from ClinicalTrials.gov:
News-Medical.net 08/05/2020 00:21
Researchers use microscopy technique to predict the course of lung cancer.
More from News-Medical.net:
Serum Exosomal miR-1290 is a Potential Biomarker for Lung Adenocarcinoma.
More from International Journal of COPD:
Medical Xpress - Cancer News 08/04/2020 14:11
Scientists accelerate progress in preventing drug resistance in lung and pancreas cancers.
More from Medical Xpress - Cancer News:
Background: Non-small cell lung cancer (NSCLC) is a molecularly heterogeneous disease with a high propensity for drug resistance and metastasis. AXL, a member of the Tyro3-AXL-Mer (TAM) family of receptor tyrosine kinases, is a central regulator of epithelial-to-mesenchymal transition (EMT) and enables tumor cells to invade and acquire drug resistance. AXL is overexpressed in NSCLC and its expression correlates positively with tumor invasion, drug resistance, and negatively predicts overall survival. We mechanistically interrogated the effects of the AXL inhibitor, TP-0903, on EMT in NSCLC cells using transcriptomic and proteomic profiling. Methods: Atomic force microscopy, Western blot analysis, RNA sequencing, and mass cytometry (CyTOF) w.
More from Molecular Cancer Research - Recent Issues (abstracts):
PubMed News (NIH) 08/04/2020
Here, we show that in lung cancer, interaction between paxillin (PXN) and integrin b4 (ITGB4), components of the focal adhesion (FA) complex, contributes to cisplatin resistance.
More from PubMed News (NIH):
Healio News 08/03/2020 09:51
Back to Healio People with interstitial lung abnormalities have an increased risk for lung cancer and lung cancer mortality, but not other cancers, according to a study published in the European Respiratory Journal.
More from Healio News:
Lung Cancer Blog 08/03/2020 04:11
Lung cancer continues to be one of the most common cancers worldwide and claims even more lives than breast, colon and prostate cancer yearly.
More from Lung Cancer Blog:
Whether DDR alterations are associated with clinical outcomes to programmed death ligand 1 [PD-(L)1] blockade in non–small cell lung cancer (NSCLC) is unknown.
More from Clinical Cancer Research - Recent Issues (abstracts):
Background:. IFN is a pleiotropic cytokine that plays critical immunomodulatory roles in intercellular communication in innate and adaptive immune responses. Despite recognition of IFN signaling effects on host defense against viral infection and its utility in immunotherapy and tumor progression, the roles of genetic variants of the IFN signaling pathway genes in survival of patients with cancer remain unknown. Methods:. We used a discovery genotyping dataset from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial ( n = 1,185) and a replication genotyping dataset from the Harvard Lung Cancer Susceptibility Study ( n = 984) to evaluate associations between 14,553 genetic variants in 150 IFN pathway genes and survival of non–sma.
More from Cancer Epidemiology, Biomarkers & Prevention Recent Issues (abstracts):
PharmiWeb.com 08/03/2020 01:36
Non-small cell lung cancer accounts for approximately 85% of all lung cancers.
More from PharmiWeb.com:
GlobeNewswire 08/03/2020 01:00
Our goal is to provide an effective treatment option for every person diagnosed with lung cancer.
More from GlobeNewswire:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications